NO20054778L - Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer - Google Patents

Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Info

Publication number
NO20054778L
NO20054778L NO20054778A NO20054778A NO20054778L NO 20054778 L NO20054778 L NO 20054778L NO 20054778 A NO20054778 A NO 20054778A NO 20054778 A NO20054778 A NO 20054778A NO 20054778 L NO20054778 L NO 20054778L
Authority
NO
Norway
Prior art keywords
rapamycin
inflammatory
treatment
combination
pharmaceutical compositions
Prior art date
Application number
NO20054778A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054778D0 (no
Inventor
Henrietta Moore
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33032928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054778(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0306070A external-priority patent/GB0306070D0/en
Priority claimed from GB0306868A external-priority patent/GB0306868D0/en
Priority claimed from GB0319226A external-priority patent/GB0319226D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20054778D0 publication Critical patent/NO20054778D0/no
Publication of NO20054778L publication Critical patent/NO20054778L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
NO20054778A 2003-03-17 2005-10-17 Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer NO20054778L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0306070A GB0306070D0 (en) 2003-03-17 2003-03-17 Organic compounds
GB0306868A GB0306868D0 (en) 2003-03-25 2003-03-25 Organic compounds
GB0319226A GB0319226D0 (en) 2003-08-15 2003-08-15 Organic compounds
PCT/EP2004/002714 WO2004082681A1 (en) 2003-03-17 2004-03-16 Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation- and ummunologically-mediated diseases

Publications (2)

Publication Number Publication Date
NO20054778D0 NO20054778D0 (no) 2005-10-17
NO20054778L true NO20054778L (no) 2005-12-19

Family

ID=33032928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054778A NO20054778L (no) 2003-03-17 2005-10-17 Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer

Country Status (26)

Country Link
US (1) US20060154952A1 (es)
EP (1) EP1608368B8 (es)
JP (1) JP2006515017A (es)
KR (1) KR100855140B1 (es)
AR (1) AR043504A1 (es)
AT (1) ATE409479T1 (es)
AU (1) AU2004222563B2 (es)
BR (1) BRPI0408423A (es)
CA (2) CA2633287A1 (es)
CL (1) CL2004000535A1 (es)
DE (1) DE602004016830D1 (es)
EC (1) ECSP056006A (es)
ES (1) ES2315648T3 (es)
HK (1) HK1086743A1 (es)
HR (1) HRP20050800A2 (es)
IS (1) IS8028A (es)
MA (1) MA27671A1 (es)
MX (1) MXPA05009934A (es)
MY (1) MY137868A (es)
NO (1) NO20054778L (es)
PE (1) PE20050313A1 (es)
PL (1) PL1608368T3 (es)
PT (1) PT1608368E (es)
TN (1) TNSN05197A1 (es)
TW (2) TW200503703A (es)
WO (1) WO2004082681A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528145B2 (en) * 2004-10-28 2009-05-05 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma
WO2009117669A2 (en) * 2008-03-21 2009-09-24 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP5766124B2 (ja) * 2009-01-21 2015-08-19 アムジェン インコーポレイテッド 炎症性疾患および自己免疫疾患の処置の組成物および方法
RU2449806C1 (ru) * 2010-11-30 2012-05-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ лечения красного плоского лишая слизистой оболочки полости рта
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
US10307370B2 (en) 2013-10-08 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
HUE062742T2 (hu) * 2014-04-04 2023-12-28 Ai Therapeutics Inc Belélegezhetõ rapamicin készítmény életkorral kapcsolatos állapotok kezelésére
MX2017004440A (es) 2014-10-07 2017-11-01 Lam Therapeutics Inc Una formulacion de rapamicina inhalable para el tratamiento de hipertension pulmonar.
TN2017000432A1 (en) 2015-04-10 2019-04-12 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427680B1 (en) * 1989-11-09 1995-08-23 Sandoz Ltd. Heteroatoms-containing tricyclic compounds
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
PT1208847E (pt) * 1996-07-30 2007-07-24 Novartis Ag Composições farmacêuticas para o tratamento da rejeição de transplantes, doenças autoimunes ou inflamatórias compreendendo ciclosporina a e 40-0-(2-hidroxietil)-rapamicina
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
US20030119797A1 (en) * 2001-05-09 2003-06-26 Salah-Dine Chibout Methods for selective immunomodulation
PL369671A1 (en) * 2002-01-10 2005-05-02 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
EP1501565B1 (de) * 2002-05-09 2006-11-02 Hemoteq GmbH Verbindungen und verfahren zur hemokompatiblen beschichtung von oberflächen

Also Published As

Publication number Publication date
TW200503703A (en) 2005-02-01
MA27671A1 (fr) 2005-12-01
TW200835484A (en) 2008-09-01
HRP20050800A2 (en) 2006-11-30
EP1608368A1 (en) 2005-12-28
BRPI0408423A (pt) 2006-03-21
JP2006515017A (ja) 2006-05-18
EP1608368B1 (en) 2008-10-01
PE20050313A1 (es) 2005-06-14
DE602004016830D1 (de) 2008-11-13
WO2004082681B1 (en) 2004-11-25
CA2517671A1 (en) 2004-09-30
PT1608368E (pt) 2009-01-27
ATE409479T1 (de) 2008-10-15
MXPA05009934A (es) 2006-03-21
AR043504A1 (es) 2005-08-03
TNSN05197A1 (en) 2007-06-11
AU2004222563A1 (en) 2004-09-30
CA2633287A1 (en) 2004-09-30
CL2004000535A1 (es) 2005-01-14
ECSP056006A (es) 2006-01-27
ES2315648T3 (es) 2009-04-01
KR100855140B1 (ko) 2008-08-28
KR20050110023A (ko) 2005-11-22
NO20054778D0 (no) 2005-10-17
MY137868A (en) 2009-03-31
IS8028A (is) 2005-09-15
WO2004082681A1 (en) 2004-09-30
EP1608368B8 (en) 2009-06-10
US20060154952A1 (en) 2006-07-13
AU2004222563B2 (en) 2006-11-02
PL1608368T3 (pl) 2009-03-31
HK1086743A1 (en) 2006-09-29

Similar Documents

Publication Publication Date Title
NO20054778L (no) Farmasoytiske sammensetninger som innbefatter en kombinasjon av rapamycin eller dets derivat og pimecrolimus for behandling av inflamasjon- og immunologisk-medierte sykdommer
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
AP2008A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them
ATE382353T1 (de) Substiuierte piperidine als melanocortinrezeptor- modulatoren
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20063928L (no) Substituerte kinolinforbindelser
NO20061363L (no) Pyrazolo- og imidazo- pyrimidinderivater
EA200802058A1 (ru) Производные циклоалкиламинокислот и их фармацевтические композиции
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
NO20084005L (no) Aminderivater
ATE361288T1 (de) N-(3,-dimethylindolin-6-yl)ä2-ä(4-
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
DE602004024900D1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
CY1107301T1 (el) Ιμιδαζο και θειαζολοπυριδινες ως αναστολεις κινασης jak3
CY1109055T1 (el) 11-((4r,6r)-4,5,6-τριϋδροξυ-3-(r)-υδροξυ-εξυλοκαρβαμοϋλο)-ενδεκαϊνικο οξυ
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application